Evaxion's AI Platform Shows Scalability for Glioblastoma Vaccine Development
EVAX has more than doubled off its 52-week low of $1.25.
Summary
Evaxion announced new data demonstrating its AI-Immunology™ platform's ability to identify novel targets for glioblastoma vaccines, including endogenous retrovirus-derived antigens, which will be presented at AACR.
Key Events · Product Development and Regulatory · EVAX
-
AI Platform Scalability Confirmed
New data demonstrates the AI-Immunology™ platform's unique scalability for developing vaccines, specifically for glioblastoma.
-
Novel Glioblastoma Targets Identified
The platform successfully identified endogenous retrovirus (ERV)-derived antigens in glioblastoma tumor samples, offering a new source of targets for cancer vaccines.
-
Collaboration with Duke University
Data analysis was conducted in collaboration with researchers at Duke University School of Medicine.
-
AACR Presentation Scheduled
The new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 22, 2026.
Analysis · EVAX · Life Sciences
This filing highlights a significant expansion of Evaxion's AI-Immunology™ platform, demonstrating its unique scalability and potential to develop vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The identification of endogenous retrovirus (ERV)-derived antigens as novel targets is particularly important, as glioblastoma typically has a low mutational burden, making traditional neoantigen targeting challenging. This "Proof-of-Concept" data, developed in collaboration with Duke University, validates the platform's versatility and opens new avenues for personalized cancer vaccine strategies, potentially enhancing efficacy for patients with high unmet medical needs. The presentation at the AACR Annual Meeting will provide further visibility and discussion opportunities with scientific and business partners.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $1.25 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.